Methylene Blue: Pharmacology, Dose and the Serotonin Problem

What it is

Methylene blue is a phenothiazine dye synthesised in 1876 and used in medicine for well over a century. It has an approved indication for acquired methaemoglobinaemia and a long history of other uses. It is not a novel compound and it is not a mystery.

Its behaviour comes from redox cycling: it accepts and donates electrons readily, which lets it act as an alternative electron carrier in the mitochondrial electron transport chain. That is the basis of the cellular-energy rationale.

The hormetic dose curve

Methylene blue is a textbook example of a biphasic, dose-dependent agent. At low concentrations it supports electron transport and acts as an antioxidant. At higher concentrations the same redox activity generates oxidative stress and impairs mitochondrial function.

More is not better. It is a different, opposite effect. This is unusual enough that it deserves emphasis: the compound is not simply weaker at low dose and stronger at high dose.

The interaction that matters most

Methylene blue is a potent inhibitor of monoamine oxidase A. This is well established and it is the reason the FDA issued a drug safety communication about serotonin syndrome risk when it is combined with serotonergic agents.

That means SSRIs, SNRIs, tricyclics, MAOIs, triptans, tramadol, and other serotonergic drugs. Serotonin syndrome is potentially life-threatening. This is not a theoretical interaction and it is not something to manage by spacing doses.

A second contraindication: people with G6PD deficiency can develop haemolysis, and methylene blue may paradoxically worsen rather than treat methaemoglobinaemia in that population.

Quality is unusually important here

Industrial-grade methylene blue is a textile dye and can carry heavy metal contamination. Pharmaceutical grade is a meaningfully different specification, and this is one of the clearest cases where grade genuinely matters.

Blue or green discolouration of urine is expected and harmless. It is the most reliable indication that you have taken it.

The reasonable position

Real pharmacology, a narrow sensible dose range, a serious and specific drug interaction, and human outcome evidence for the cognitive claims that is preliminary.

Anyone taking an antidepressant should not take methylene blue without speaking to their prescriber first. This is educational content, not medical advice.